Mary Caffrey

Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.

Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.

Articles by Mary Caffrey

Greetings from First Lady Michelle Obama and a lecture from a non-cardiologist on population health set the stage for the 65th Scientific Session of the American College of Cardiology. Prevention is the focus of this year's meeting.

Study authors found that women whose mammograms revealed calcium buildup in breast arteries were highly likely to have coronary arterial calcification. This "practice changing" finding could allow doctors to spot early heart disease in women where it otherwise would have been missed.

An estimated 29.1 million Americans have diabetes; most have type 2 disease. While the CDC reported in December that new cases had fallen for the first time in a generation, there are disparities in who gets the disease. It hits harder among the poor and minorities.

In Soda Politics, Marion Nestle, PhD, traces the history of the giant soda companies in the United States, and how they have copied the tactics of Big Tobacco to get children "drinking sugar," with resulting rates of diabetes and obesity. Other groups are joining Nestle in criticizing the export of heavy soda marketing to the developing world.

Regeneron and Sanofi vowed to appeal the ruling; analysts said that process could take at least a year. While Amgen has asked for a permanent injunction, some see payment of royalties to Amgen as a more likely outcome if Regeneron is ultimately not successful.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo